股票代码：002020 股票简称：京新药业 编号：2023-005 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他 （请文字说明其他活动内容） | --- | |----------------------------------------------------------| | 山西证券魏赟；上海证券张林晚；华安证券丁冉；华泰证券刘 | | 诗瑶、宋磊、唐庆雷；湘财证券蒋栋；长城证券李华云；东方 | | 基金王芳玲；德邦证券吴沛柯；珠海汇尚创业投资龚元喆；华 | | 西证券孙子豪、王帅；申万宏源李敏杰、张静含；上海瞰道资 | | 产管理有限公司周帅；上海滚石投资胡小军；江苏佳鸿私募基 | | 金韩金斌；上海华石投资谢风华；鹏扬基金伍智勇；上海福实 | | 投资路永光；上海枫池资产邢哲；贝莱德基金秦瑶函；曼林（山 | | 东）私募（投资）基金陈昊宇；深圳市国诚投资相健、王秋楠、 | | 王文强；万和证券唐伟民；上海正淄资产谢凌；上海鹏泰投资 | | 祝凯伦；璞智投资温灵军；国鸣投资张同鑫、郑博；东方财富 | | 证券侯伟青；华融证 ...

Financial Performance - The company's revenue for Q1 2023 was ¥960,425,636.79, representing a 10.32% increase compared to ¥870,570,379.68 in the same period last year[7] - Net profit attributable to shareholders for Q1 2023 was ¥151,198,043.53, up 10.15% from ¥137,264,079.65 in the previous year[7] - The net profit after deducting non-recurring gains and losses was ¥137,301,166.62, reflecting a 7.03% increase from ¥128,283,249.09 year-on-year[7] - Basic and diluted earnings per share for Q1 2023 were both ¥0.18, a 12.50% increase from ¥0.16 in the previous year[7] - The net profit for the first quarter of 2023 was CNY 151,748,477.91, an increase of 10.3% compared to CNY 137,868,319.80 in the same period last year[20] - Operating profit reached CNY 174,895,031.53, up from CNY 155,172,110.78, reflecting a growth of 12.5% year-over-year[20] - The total comprehensive income for the period was CNY 151,899,910.63, compared to CNY 138,090,753.91, reflecting a growth of 10.5%[20] Cash Flow - The net cash flow from operating activities for Q1 2023 was ¥198,885,534.01, an increase of 17.49% compared to ¥169,274,493.96 in the same period last year[7] - Cash flow from operating activities was CNY 960,499,528.42, significantly higher than CNY 819,919,186.12 in the previous year, indicating a growth of 17.1%[20] - The net cash inflow from operating activities was CNY 198,885,534.01, an increase from CNY 169,274,493.96 in the previous period, representing a growth of 17.5%[21] - The total cash inflow from investment activities was CNY 414,721,912.54, compared to CNY 458,586,902.49 in the previous period, showing a decrease of 9.5%[21] - The net cash outflow from investment activities was CNY -257,496,231.46, worsening from CNY -177,508,796.25, indicating a decline of 45.06%[28] - The net cash outflow from financing activities was CNY -16,034,763.82, a significant decrease from CNY 884,532.86, reflecting a decline of 1912.79%[28] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥7,554,114,668.34, a 2.60% increase from ¥7,362,555,862.94 at the end of the previous year[7] - The company's non-current assets totaled CNY 4,316,212,532.94, an increase from CNY 4,081,390,078.48, showing a growth of 5.8%[20] - The total liabilities increased to CNY 1,862,260,191.83, compared to CNY 1,815,386,168.87, indicating a rise of 2.6%[20] - The total liabilities rose to ¥2,230,250,203.54 from ¥2,190,585,660.02, representing an increase of 1.8%[35] - The total current assets decreased to CNY 3,237,902,135.40 from CNY 3,281,165,784.46, reflecting a decline of 1.32%[33] - The inventory decreased to CNY 759,947,925.00 from CNY 773,699,559.82, indicating a reduction of 1.77%[33] Shareholder Equity - Shareholders' equity attributable to the parent company was ¥5,297,451,911.83, up 2.94% from ¥5,146,123,375.50 at the end of the previous year[7] - Total equity attributable to shareholders reached ¥5,297,451,911.83, up from ¥5,146,123,375.50, marking a growth of 2.9%[35] Government Support and Other Income - The company received government subsidies amounting to ¥12,519,639.92 during the reporting period[9] - Other income increased to ¥12,519,639.92 from ¥5,109,676.74, indicating enhanced revenue streams[35] Research and Development - Research and development expenses were ¥80,838,157.33, slightly higher than ¥79,224,664.20 from the previous period, indicating a focus on innovation[35] Financial Performance Metrics - The weighted average return on equity for Q1 2023 was 2.90%, an increase of 0.05 percentage points from 2.85% in the previous year[7] - The company's receivables financing increased by 169.41% to CNY 94,671,788.87 from CNY 35,140,735.52[28] - The construction in progress rose by 37.86% to CNY 392,776,786.14 from CNY 284,910,001.25, primarily due to increased project activities[28] - The fair value gains increased significantly by 3496.10% to CNY 596,602.74 from CNY 16,590.27, attributed to higher financial product returns[28] - The company reported a financial income of ¥6,243,887.32, a significant improvement compared to a financial expense of ¥14,113,355.55 in the previous period[35]

投资者关系活动类 别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 员姓名 线上参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 04 月 14 日（星期五）下午 15:00-17:00 地点 "京新药业投资者关系"微信小程序 上市公司接待人员 姓名 董事兼总裁：金志平先生 董事兼董事会秘书：洪贇飞先生 董事兼副总裁、财务总监：陈美丽女士 独立董事：张大亮先生 投资者关系活动主 要内容介绍 投资者关系活动主要内容详见附件一。 附件清单（如有） 附件一：京新药业 2022 年度网上业绩说明会问答清单 日期 2023 年 04 月 14 日 1 2 序号 问题内容 回答内容 1 地达西尼上市预期是怎样的？定价方面 采用何种策略。该领域的市场竞争格局怎 样？ 失眠市场整体规模及市场上已有品种的销售 规模都说明存在较大的市场需求，近期也少有 创新药上市，我们看好地达西尼上市后的销售 前景。定价方面我们会结合药物经济学、供应 链、市场竞争环境、患者的支付能力等综合评 估后制定一个相对合理的价格。谢谢。 ...

浙江京新药业股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 浙江京新药业股份有限公司（以下简称"公司"）已于2023年3月30日在巨潮资讯网 （http://www.cninfo.com.cn/）上披露了《2022年年度报告》及摘要。为便于广大投资者进 一步了解公司2022年年度经营情况，公司定于2023年4月14日（星期五）15:00—17:00在"京 新药业投资者关系"小程序举行2022年度网上业绩说明会。投资者可通过以下方式参与，具体 如下： 证券代码：002020 证券简称：京新药业 公告编号：2023018 3、出席本次说明会的人员 公司董事兼总裁金志平先生，董事兼董事会秘书洪贇飞先生，董事兼副总裁、财务总监陈 美丽女士，独立董事张大亮先生（如有特殊情况，参与人员会有调整）。 4、投资者问题征集及方式 为广泛听取投资者的意见和建议，提前向投资者征集问题，提问通道自发出公告之日起开 放，投资者可以于2023年4月13日(星期四) 15:00 前通过上述投资者参与方式进入"京新药业 2022年度业绩 ...

R&D and Innovation - The company has established a comprehensive industrial chain layout and has been recognized as a "National Technology Innovation Demonstration Enterprise" in 2020, enhancing its core competitiveness in R&D[1] - The R&D team consists of over 960 technical personnel, accounting for approximately 23% of the total workforce, with more than 260 holding master's or doctoral degrees, representing about 30% of the technical staff[4] - The company is committed to developing innovative drugs and technologies, with a focus on the mental health and cardiovascular sectors, while also exploring opportunities in traditional Chinese medicine and medical devices[25] - The company has established a comprehensive marketing network covering commercial channels, retail pharmacies, and hospitals, enhancing its brand recognition and market influence[41] - The company has successfully entered the medical device sector through the acquisition of Shenzhen Juyun, expanding its business scope beyond pharmaceuticals[39] - The company has registered and approved 3 new generic drugs and initiated nearly 20 new R&D projects during the reporting period[114] - The company plans to submit over 10 generic drug applications annually, enhancing its competitive edge in the generic drug market[1] - The company is actively exploring new drug targets with significant clinical application potential, focusing on unmet clinical needs[101] - The company plans to enhance its innovative drug R&D capabilities and expand its product pipeline in core areas[175] - The company intends to innovate with over 4 new drug projects and aims to enhance its product pipeline through both external collaborations and internal initiatives[192] Market Position and Performance - The company is a leading player in the CNS field, with its anti-epileptic drug, Levetiracetam, ranking first in the national hospital market, and its Parkinson's treatment, Pramipexole, ranking first among domestic products[10] - The company has a strong market position in the medical imaging display sector, with a market share exceeding 50% in China, partnering with major global equipment manufacturers[10] - The company achieved a net cash flow from operating activities of ¥407,389,828.23 in Q3, significantly higher than Q2's ¥104,751,744.11[79] - The company reported a total net profit of approximately 59.26 million in the current period, with a significant increase compared to previous periods[36] - The company’s gross margin for main business was 52.85%, a decrease of 2.01% from the previous year[1] - The company achieved a 20.30% increase in overseas revenue, totaling ¥715,379,235.17, compared to ¥594,659,483.69 in 2021[132] - The company’s market share in key hospitals has been steadily increasing, with nearly 40% of finished drug revenue coming from centralized procurement sales[110] - The company has established itself as one of the most influential players in the domestic neuropsychiatric market through successful products like Levetiracetam and Sertraline[62] Financial Performance - Total revenue for 2022 reached ¥3,779,846,285.48, representing a year-on-year increase of 9.04% compared to ¥3,466,550,155.82 in 2021[132] - Net assets attributable to shareholders reached ¥5,146,123,375.50, reflecting a 5.85% increase from ¥4,861,543,020.01[78] - The company reported a 14.40% increase in net profit after deducting non-recurring gains and losses, reaching ¥602,992,689.68[88] - The company’s R&D expenditure for the year was CNY 367 million, up 9.68% year-on-year, supporting ongoing innovation and generic drug development[114] - The sales revenue from medical devices was CNY 629 million, with a year-on-year growth of 13.65%[110] - The company’s solid dosage production capacity enhancement project aims for an annual output of 3 billion tablets[115] - The company’s total investment for the reporting period was CNY 1,873,362.60, a 12.40% increase compared to the previous year[148] - The company’s cash inflow from financing activities decreased by 64.06% to CNY 239,765,754.71 in 2022, indicating a reduction in capital raised compared to the previous year[158] Challenges and Strategic Adjustments - The company faced significant challenges due to "collective procurement," with sales of certain key products dropping by over 66%[46] - The company successfully stabilized its operating performance by rapidly adjusting strategies and focusing on the sales of its neuropsychiatric product line[46] - The company acknowledges the challenges posed by changing economic and political environments and is adjusting its strategies to align with national pharmaceutical policies[194] - The company faces risks related to industry policy changes, R&D challenges, and talent shortages, and is implementing measures to mitigate these risks[177][178][179] Supply Chain and Management - The company has established long-term cooperative relationships with key suppliers to ensure the stability and effectiveness of its supply chain[5] - The company has a stable and experienced management team that continuously enhances operational capabilities and optimizes the management structure to maintain competitive advantages in the industry[3] - The company employs a sales model based on customer demand and maintains appropriate safety stock levels to optimize production planning[31] - The company is focusing on lean production and capacity building to establish a competitive cost advantage[176] Future Outlook - The company aims for continuous healthy growth in revenue and net profit by improving internal management quality and operational efficiency[25] - The company plans to focus on the strategic areas of mental health and cardiovascular diseases, aiming for continuous improvement in operational performance and sustainable growth in 2023[191] - The company is focused on international market expansion by optimizing resource allocation and improving customer structure to enhance international business growth[193] - The company is dedicated to maintaining high environmental standards in its manufacturing processes to ensure sustainable development[196]